ZDLD20
ZDLD20, a β-carboline, is orally active and selective CDK4/CycD3 inhibitor with an IC50 value of 6.51 μM. ZDLD20 exhibits potent anti-HCT116 activity including inhibition of colony formation, inhibition of invasion and migration, inducing of apoptosis, and arresting of G1 phase in cell cycle. ZDLD20 exhibits potent anticancer activity[1].
Product Specifications
CAS Number
[2762279-02-5]
UNSPSC
12352005
Target
CDK
Type
Reference compound
Related Pathways
Cell Cycle/DNA Damage
Applications
Cancer-Kinase/protease
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/zdld20.html
Purity
99.84
Solubility
DMSO : 25 mg/mL (ultrasonic; warming; heat to 60°C)
Smiles
O=C(C1=NC=CC2=C1NC3=C2C=CC=C3)NC4=NC=C(N5CCN(C)CC5)C=C4
Molecular Formula
C22H22N6O
Molecular Weight
386.45
References & Citations
[1]Deping Li, et al. Facile synthesis of C1-substituted β-carbolines as CDK4 inhibitors for the treatment of cancer. Bioorg Chem. 2022 Apr;121:105659.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Isoform
CDK4
Available Sizes
Explore Other Products
Browse additional items from our catalog
Lentiviral human IQCC sgRNA gene knockout kit - Lentiviral human IQCC sgRNA gene knockout kit (plasmid)
4930579J09Rik-set siRNA/shRNA/RNAi Lentivector (Mouse)
